Similarly, in cross-sectional studies involving patients with heart failure, aortic stenosis, coronary artery disease and atrial fibrillation, the use of ACEi or ARBs did not affect plasma ACE2 activity in comparison with untreated patients [61–63]. This evidence concerns the gene ACE2 and heart failure.